-
Rescaled Tariff Regression for EQ-5D-5L Health State Valuation: An Equivalent Alternative to the Nonparametric Crosswalk
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Pegunigalsidase Alfa Compared to Agalsidase Alfa and Agalsidase Beta for the Treatment of Adult Patients With Fabry Disease in Greece
Sep 9, 2025, 16:22 PM -
A Gap Analysis of HTA Methods in Europe: Results From SUSTAIN-HTA
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Pegcetacoplan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients With Treatment Failure After C5 Inhibitor Therapy: An Analysis From the Brazilian Public Healthcare System Perspective
Sep 9, 2025, 16:22 PM -
A Disease Progression Model Comparing Respiratory and Motor Decline in People With Late-Onset Pompe Disease Treated With Cipaglucosidase Alfa Plus Miglustat vs. Alglucosidase Alfa
Sep 9, 2025, 16:22 PM -
A NICE Idea? Assessing the Impact of the Severity Modifier in Oncology and Nononcology Single Technology Appraisals
Sep 9, 2025, 16:22 PM -
The Effect of Pharmaceutical Pricing Policies on Healthcare Expenditures in Turkey: Analysis for the Period 2015-2024
Sep 9, 2025, 16:22 PM -
Knowledge and Awareness of Primary Care Physicians (PCPs) Towards Respiratory Syncytial Virus (RSV) in Australia, Hong Kong, Japan, New Zealand, South Korea, Singapore, and Taiwan
Sep 9, 2025, 16:22 PM -
Burden of Bloodstream Infections in the United States: Incidence and Healthcare Resource Utilization 2022-2024
Sep 9, 2025, 16:22 PM -
A Review of the UK's International Recognition Procedure and Its Role in Expediting Access to Innovative Treatments
Sep 9, 2025, 16:22 PM -
Economic Evaluations of First-Line Non-Small Cell Lung Cancer Therapies: A Systematic Review With Focus on PD-L1 Subgroups
Sep 9, 2025, 16:22 PM -
Micro-Costing Analysis of the Economic Burden of Metabolic Dysfunction-Associated Steatohepatitis and Its Comorbidities in Saudi Arabia
Sep 9, 2025, 16:22 PM -
English Translation, Cross-Cultural Adaptation and Validation of the French New Patient-Reported Outcome Measures of the Multiple Sclerosis Autonomy Scale (MSAS)
Sep 9, 2025, 16:22 PM -
Navigating Three Systems: A Comparative Analysis of Pharmaceutical Reimbursement in Germany, Austria, and Switzerland
Sep 9, 2025, 16:22 PM -
Predictive Algorithms in HTA: What Factors Influence Decision Making in NICE, SMC, and NCPE?
Sep 9, 2025, 16:22 PM -
Evaluating the Use of Large Language Models (LLM) in Summarizing Treatment Guidelines: A Pilot Study
Sep 9, 2025, 16:22 PM -
Too Good to Be True? Social Desirability Bias in Age-Related Patterns of Self-Reported Medication Adherence Among Patients With Atrial Fibrillation
Sep 9, 2025, 16:22 PM -
Exploring Artificial Intelligence's (AI's) Role in Literature Screening: A Comparative Analysis Paving the Way for More Efficient Evidence Synthesis
Sep 9, 2025, 16:22 PM -
Extent and Causes of the Collapse in the Registration of Innovative Medications in Lebanon: A Mixed-Methods Analysis
Sep 9, 2025, 16:22 PM -
Improving Indirect Treatment Comparisons via an Alternative MAIC Patient Weighting Method
Sep 9, 2025, 16:22 PM
